Cheyenne Newsome, PharmD, PhC, BCACP, clinical assistant professor at the Washington State University College of Pharmacy, discusses the health disparities seen in the LGBTQ community and what considerations providers should keep in mind when treating transgender patients.
HIV is not associated with preterm delivery, though antiretroviral therapy is, but hepatitis C may be a potential risk factor.
While scientists know more about the HIV infection than ever, and can prevent it from progressing into AIDS, there is still no known cure for the virus.
A look at last week's top stories in the world of pharmacy.
New platform would allow health care providers in developing nations to perform easy HIV testing and monitoring.
The Task Force notes in the draft recommendations that clinicians should screen everyone between the ages 15 to 65 years and all pregnant women for HIV.
Fostemsavir (ViiV Healthcare) may be a potential new option for patients with HIV who have become resistant to other medications.
New recommendations urge health care providers to offer pre-exposure prophylaxis (PrEP) to individuals at high risk of HIV.
Antiretroviral drug treatment was not found to be a cause of the higher prevalence of hypertension in persons infected with HIV.
Cellular proliferation predominantly drives HIV persistence on antiretroviral therapy, according to a new study.
Top news of the day from across the health care landscape.
Hispanic adults in the US who are infected with human immunodeficiency virus face a greater risk of cancers caused by human papillomavirus (HPV) than Hispanics in the general public.
The FDA has approved lamivudine and tenofovir disoproxil fumarate (Temixys, Celltrion) tablets, 300 mg/300 mg in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adult and pediatric patients weighing at least 35 kg.
Research on nonalcoholic fatty liver disease (NAFLD) in persons infected with HIV revealed a prevalence of the condition of about 40%, suggesting the condition may be an underappreciated comorbidity in this population.
Sofosbuvir, velpatasvir, and voxilaprevir successful in patients with hepatitis C virus infection, with and without HIV co-infection, including those with prior noncompletion of treatment or poor adherence to direct-acting antiviral drug regimens.
Stigma may cause undiagnosed individuals with HIV to go unidentified and fail to get quality care and treatment.
Several large investigations have demonstrated the considerable efficacy of TDF/FTC taken daily or intermittently, reducing the risk of HIV acquisition by more than 95% in high-risk individuals.
A total of 85% of AMBER study participants (308/362) achieved virologic suppression (viral load
Preliminary data show that treatment with anti-PD-1 inhibitors may be feasible in patients with HIV and cancer.
Hepatitis C virus found to increase mortality in individuals coinfected with HIV, however, treatment with direct-acting antivirals may reduce harm.
Top news of the week from Specialty Pharmacy Times.
New analysis examines the role of the HIV/AIDS epidemic in cancer survival rates among adolescents and young adults.
Coinfection with HIV and tuberculosis may affect drug-related adverse events, hospital readmissions, and treatment duration.
ViiV Healthcare has submitted a New Drug Application (NDA) for its single-tablet, 2-drug regimen of dolutegravir (DTG) and lamivudine (3TC) for the treatment of HIV-1 infection.
Dolutegravir plus lamivudine showed non-inferiority to a 3-drug, first-line regimen in treating HIV infection.
